Evidence for the specificity for platelet HPA-1a alloepitope and the presenting HLA-DR52a of diverse antigen-specific helper T cell clones from alloimmunized mothers

Journal of Immunology

Volumn 183, Issue 1, 2009, Pages 677-686

  Rayment, Rachel ^a,b   Kooij, Taco W ^a   Zhang, Wei ^a   Siebold, Christian ^c   Murphy, Mike F ^a   Allen, Dave ^a   Willcox, Nick ^a   Roberts, David J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO ACID; HLA ANTIGEN CLASS 2; HLA DR3 ANTIGEN; HLA DR52 ANTIGEN; T LYMPHOCYTE RECEPTOR; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; 1A ALLOANTIGEN, HUMAN; ALLOANTIBODY; EPITOPE; HLA DR ANTIGEN;

ALLOIMMUNIZATION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ANCHORAGE; CELL CLONING; CELL ISOLATION; CRYSTAL STRUCTURE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; IMMUNOTHERAPY; IN VIVO STUDY; LYMPHOCYTE CLONE; MOLECULAR MODEL; PRIORITY JOURNAL; TH1 CELL; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BIOSYNTHESIS; BLOOD; CELL CLONE; CELL CULTURE; COCULTURE; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOTHER;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, HUMAN PLATELET; CELLS, CULTURED; CLONE CELLS; COCULTURE TECHNIQUES; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-DR ANTIGENS; HUMANS; ISOANTIBODIES; MOLECULAR SEQUENCE DATA; MOTHERS; TH1 CELLS;

EID: 68949149155     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801473     Document Type: Article

References (44)

1. Stott, L. M., R. N. Barker, and S. J. Urbaniak. 2000. Identification of alloreactive T-cell epitopes on the rhesus D protein. Blood 96: 4011-4019.
2. Maslanka, K., M. Yassai, and J. Gorski. 1996. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J. Clin. Invest. 98: 1802-1808. (Pubitemid 26359197)
3. Sukati, H., H. Bessos, R. N. Barker, and S. J. Urbaniak. 2005. Characterization of the alloreactive helper T-cell response to the platelet membrane glycoprotein IIIa (integrin-β3) in human platelet antigen-1a alloimmunized human platelet antigen-1b1b women. Transfusion 45: 1165-1177.
4. Turner, M. L., H. Bessos, T. Fagge, M. Harkness, F. Rentoul, J. Seymour, D. Wilson, I. Gray, R. Ahya, J. Cairns, and S. Urbaniak. 2005. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 45: 1945-1956.
5. Murphy, M. F., and J. B. Bussel. 2007. Advances in the management of alloimmune thrombocytopenia. Br. J. Haematol. 136: 366-378.
6. Bussel, J. B., and A. Primiani. 2008. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev. 22: 33-52.
7. Paidas, M. J., R. L. Berkowitz, L. Lynch, C. J. Lockwood, R. Lapinski, J. G. McFarland, and J. B. Bussel. 1995. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am. J. Obstet. Gynecol. 172: 475-479.
8. Kaplan, C. 2007. Neonatal alloimmune thrombocytopenia: a 50 year story. Immunohematology 23: 9-13. (Pubitemid 46608790)
9. Ghevaert, C., K. Campbell, J. Walton, G. A. Smith, D. Allen, L. M. Williamson, W. H. Ouwehand, and E. Ranasinghe. 2007. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 47: 901-910.
10. 3 in human platelet signal transduction. Biochem. Pharmacol. 60: 1069-1074.
11. Mueller-Eckhardt, C., V. Kiefel, A. Grubert, H. Kroll, M. Weisheit, S. Schmidt, G. Mueller-Eckhardt, and S. Santoso. 1989. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1: 363-366. (Pubitemid 19103082)
12. Newman, P. J., R. S. Derbes, and R. H. Aster. 1989. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J. Clin. Invest. 83: 1778-1781.
13. Valentin, N., A. Vergracht, J. D. Bignon, M. L. Cheneau, D. Blanchard, C. Kaplan, M. F. Reznikoff-Etievant, and J. Y. Muller. 1990. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum. Immunol. 27: 73-79.
14. Wu, S., K. Maslanka, and J. Gorski. 1997. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J. Immunol. 158: 3221-3226.
15. Vieira, M. L., S. Caillat-Zucman, P. Gajdos, S. Cohen-Kaminsky, A. Casteur, and J. F. Bach. 1993. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J. Neuroimmunol. 47: 115-122.
16. Janer, M., A. Cowland, J. Picard, D. Campbell, P. Pontarotti, J. Newsom-Davis, M. Bunce, K. Welsh, A. Demaine, A. G. Wilson, and N. Willcox. 1999. A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C. Hum. Immunol. 60: 909-917.
17. Nagvekar, N., L. Corlett, L. W. Jacobson, H. Matsuo, R. Chalkley, P. C. Driscoll, S. Deshpande, E. G. Spack, and N. Willcox. 1999. Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. J. Immunol. 162: 4079-4087.
18. Hill, M., D. Beeson, P. Moss, L. Jacobson, A. Bond, L. Corlett, J. Newsom-Davis, A. Vincent, and N. Willcox. 1999. Early-onset myasthenia gravis: a recurring T-cell epitope in the adult-specific acetylcholine receptor epsilon subunit presented by the susceptibility allele HLA-DR52a. Ann. Neurol. 45: 224-231.
19. Parry, C. S., J. Gorski, and L. J. Stern. 2007. Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity. J. Mol. Biol. 371: 435-446.
20. Kimura, A., R. P. Dong, H. Harada, and T. Sasazuki. 1992. DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 40: 5-12.
21. Weekes, M. P., M. R. Wills, K. Mynard, A. J. Carmichael, and J. G. Sissons. 1999. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73: 2099-2108.
22. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
23. Ghosh, P., M. Amaya, E. Mellins, and D. C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378: 457-462.
24. Jones, E. Y., L. Fugger, J. L. Strominger, and C. Siebold. 2006. MHC class II proteins and disease: a structural perspective. Nat. Rev. 6: 271-282.
25. 3-integrin impairs the HPA-1a epitope: the third allele of HPA-1. Transfusion 46: 790-799.
26. Marsh, S. G. E., J. H. Moses, and J. G. Bodmer. 1992. HLA class II sequence polymorphism detectable by serology, in HLA 1991 XIth International Histocompatibilty Workshop. K. Tsuju, M. Aizawa, and T. Sasazuki, eds. Oxford University Press, Oxford, pp. 610-620.
27. Siebold, C., B. E. Hansen, J. R. Wyer, K. Harlos, R. E. Esnouf, A. Svejgaard, J. I. Bell, J. L. Strominger, E. Y. Jones, and L. Fugger. 2004. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc. Natl. Acad. Sci. USA 101: 1999-2004.
28. Mellins, E., B. Arp, D. Singh, B. Carreno, L. Smith, A. H. Johnson, and D. Pious. 1990. Point mutations define positions in HLA-DR3 molecules that affect antigen presentation. Proc. Natl. Acad. Sci. USA 87: 4785-4789.
29. Ong, B., N. Willcox, P. Wordsworth, D. Beeson, A. Vincent, D. Altmann, J. S. Lanchbury, G. C. Harcourt, J. I. Bell, and J. Newsom-Davis. 1991. Critical role for the Val/Gly86 HLA-DR β dimorphism in autoantigen presentation to human T cells. Proc. Natl. Acad. Sci. USA 88: 7343-7347.
30. Dessen, A., C. M. Lawrence, S. Cupo, D. M. Zaller, and D. C. Wiley. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7: 473-481. (Pubitemid 27508699)
31. Bond, A. P., L. Corlett, S. J. Curnow, E. Spack, N. Willcox, and J. Newsom-Davis. 1998. Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T-cell clone from a myasthenia gravis patient after engaging the T-cell receptor with three different ligands. J. Neuroimmunol. 82: 182-190.
32. Piemonti, L., P. Monti, P. Allavena, M. Sironi, L. Soldini, B. E. Leone, C. Socci, and V. Di Carlo. 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 162: 6473-6481.
33. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-4780. (Pubitemid 127471012)
34. Jackson, D. J., M. F. Murphy, P. W. Soothill, G. F. Lucas, C. J. Elson, and B. M. Kumpel. 2005. Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism. Clin. Exp. Immunol. 142: 92-102.
35. Matsuo, H., A. P. Batocchi, S. Hawke, M. Nicolle, L. Jacobson, A. Vincent, J. Newsom-Davis, and N. Willcox. 1995. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J. Immunol. 155: 3683-3692.
36. Kumpel, B. M., and D. J. Jackson. 2003. Immunocytochemical analysis of CD41, CD61 and human platelet antigen-1a expression in human placenta. Transfus. Med. 13(Suppl.): 36.
37. Elzey, B. D., J. Tian, R. J. Jensen, A. K. Swanson, J. R. Lees, S. R. Lentz, C. S. Stein, B. Nieswandt, Y. Wang, B. L. Davidson, and T. L. Ratliff. 2003. Platelet-mediated modulation of adaptive immunity: a communication link between innate and adaptive immune compartments. Immunity 19: 9-19.
38. Elzey, B. D., D. L. Sprague, and T. L. Ratliff. 2005. The emerging role of platelets in adaptive immunity. Cell. Immunol. 238: 1-9.
39. Rammensee, H. G. 1995. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 7: 85-96.
40. Matsuo, H., L. Corlett, S. Hawke, M. Nicolle, P. Driscoll, S. Deshpande, E. Spack, and N. Willcox. 1999. Distant interactions between dimorphisms in HLA-DR4 radically affect recognition of defined peptides by a specific T cell clone. Int. Immunol. 11: 835-843.
41. Vandiedonck, C., M. Giraud, and H. J. Garchon. 2005. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J. Autoimmun. 25(Suppl.): 6-11.
42. Grewal, I. S., K. D. Moudgil, and E. E. Sercarz. 1995. Hindrance of binding to class II major histocompatibility complex molecules by a single amino acid residue contiguous to a determinant leads to crypticity of the determinant as well as lack of response to the protein antigen. Proc. Natl. Acad. Sci. USA 92: 1779-1783.
43. Siragam, V., A. R. Crow, D. Brinc, S. Song, J. Freedman, and A. H. Lazarus. 2006. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat. Med. 12: 688-692.
44. Dzhambazov, B., K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg. 2006. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176: 1525-1533.